Significant Ownership of Sofinnova Venture Partners IX, L.P.

Signature and title
/s/ Nathalie Auber - Nathalie Auber/Attorney-in-Fact
Location
Menlo Park, CA
13D/G summary
Recent SEC Schedule 13D/G beneficial ownership filings for Sofinnova Venture Partners IX, L.P..

Follow Filing Activity

Follow Sofinnova Venture Partners IX, L.P. and return when a new Schedule 13D/G filing changes the record on this page.

This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.

Create free account and return here Already have an account? Sign in and return here

Significant Ownership of Sofinnova Venture Partners IX, L.P.

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
NXTC NextCure, Inc. Common Stock, $0.001 par value 7.1% $2,947,939 222,654 Sofinnova Venture Partners IX, L.P. ("SVP IX") 19 Dec 2025
AVBP ArriVent Biopharma, Inc. Common Stock, $0.0001 Par Value per Share 4.1% $35,767,532 1,696,752 Sofinnova Venture Partners XI, L.P. ("SVP XI") 31 Dec 2025

Schedules 13D/G Reported by Sofinnova Venture Partners IX, L.P.:

Sym Target Class Ownership Change Current shares Change Value Reporting name Form Report period Filing date
An asterisk next to the price means the reported price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .